Settlement Reached in 10x Genomics and Bruker Patent Dispute Following $31 Million Verdict

In an outcome that highlights the complexity of patent infringement suits within the biotechnology sector, 10x Genomics and Bruker Corp. have settled a lawsuit with significant implications for involved parties. This settlement follows a $31 million verdict against 10x Genomics, which previously compelled NanoString, another company embroiled in the dispute, to seek Chapter 11 bankruptcy protection. While details of the settlement remain under wraps, this legal dispute underscores the ongoing challenges and high stakes present in the biotech industry’s patent landscape.